NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer

May 29-June 2, 2015; Chicago, Illinois
Results of this phase II study indicate promising response rates and survival in both tubulin inhibitor–naive and tubulin inhibitor–exposed patients.
Format: Microsoft PowerPoint (.ppt)
File Size: 476 KB
Released: June 4, 2015


Educational grant provided by:
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Novartis Pharmaceuticals Corporation

Related Content

CME-certified Webcast of a CCO symposium at SITC 2019 featuring expert perspectives on optimal integration of immunotherapy into care of patients with bladder cancer

Elizabeth R. Plimack, MD, MS
Program Director
Matthew Galsky, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: January 23, 2020 Expiration: January 22, 2021

Download this slideset by Matthew Galsky, MD, to see recent data and ongoing clinical trials with immune checkpoint inhibitors for patients with muscle-invasive bladder cancer.

Matthew Galsky, MD Released: November 7, 2019

Download this free slideset by Elizabeth R. Plimack, MD, MS, for a summary of clinical data on the use of immune checkpoint inhibitor-based therapy for patients with metastatic urothelial carcinoma.

Elizabeth R. Plimack, MD, MS
Program Director
Released: November 7, 2019

Review key clinical data in prostate cancer and urothelial carcinoma from ASCO 2019 with this expert analysis from Daniel P. Petrylak, MD

Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 16, 2019 Expiration: August 15, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?